Ribosome biogenesis‐based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13340
Abstract: Resistance of advanced hormone‐dependent endometrial carcinoma to endocrine therapy remains a worldwide clinical issue. We recently reported that the combination of Vistusertib (V, mTOR inhibitor) and Anastrozole (A, aromatase inhibitor) improves the progression‐free rate compared… read more here.
Keywords: ribosome biogenesis; mtor inhibitor; inhibitor; endocrine therapy ... See more keywords
The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma
Sign Up to like & getrecommendations! Published in 2019 at "Magnetic Resonance in Medicine"
DOI: 10.1002/mrm.27683
Abstract: The mammalian target of rapamycin is an enzyme that regulates cell metabolism and proliferation. It is up‐regulated in aggressive tumors, such as glioblastoma, leading to increased glucose uptake and consumption. It has been suggested that… read more here.
Keywords: effect mtor; inhibitor rapamycin; mtor inhibitor; rapamycin glucocest ... See more keywords
Interleukin-1β is associated with coronary endothelial dysfunction in patients with mTOR-inhibitor-eluting stent implantation
Sign Up to like & getrecommendations! Published in 2017 at "Heart and Vessels"
DOI: 10.1007/s00380-017-0947-x
Abstract: Implantation of mammalian target of rapamycin (mTOR)-inhibitor drug-eluting stents (DESs) impairs coronary endothelial function. There are no known non-invasive biomarkers of coronary endothelial dysfunction. We aimed to assess the association between serum interleukin-1beta (IL-1β) and… read more here.
Keywords: mtor inhibitor; coronary endothelial; mtor; implantation ... See more keywords
Hyperglycemia-induced VEGF and ROS production in retinal cells is inhibited by the mTOR inhibitor, rapamycin
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-81482-3
Abstract: Determine the impact of the mTOR inhibitor, rapamycin, on the hyperglycemia-induced expression of vascular endothelial growth factor (VEGF) and the production of reactive oxygen species (ROS) in retinal cells. Rats made hyperglycemic for 8 weeks… read more here.
Keywords: inhibitor rapamycin; mtor inhibitor; hyperglycemia induced; induced vegf ... See more keywords
Observation of a possible successful treatment of DEPDC5-related epilepsy with mTOR inhibitor.
Sign Up to like & getrecommendations! Published in 2023 at "Neuropediatrics"
DOI: 10.1055/a-2104-1614
Abstract: The mechanistic target of the rapamycin signaling pathway serves as a central regulator of cell metabolism, growth, proliferation and survival. In its regulation, the GTPase-activating protein activity toward Rags1 complex has an inhibitory effect. Mutations… read more here.
Keywords: depdc5 related; epilepsy; treatment; mtor inhibitor ... See more keywords
Combination of mTOR inhibitor PP242 and AMPK activator metformin exerts enhanced inhibitory effects on colorectal carcinoma cells in vitro by blocking multiple kinase pathways.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of chemotherapy"
DOI: 10.1080/1120009x.2022.2091122
Abstract: The second-generation mammalian target of rapamycin (mTOR) inhibitor PP242 has demonstrated limited success in some rapamycin-insensitive tumours. We examined the therapeutic potential of combining PP242 with adenosine 50- monophosphate-activated protein kinase (AMPK) activator metformin, using… read more here.
Keywords: pp242; combination; kinase; ampk ... See more keywords
Effect of confounding factors on a phospho-flow assay of ribosomal S6 protein for therapeutic drug monitoring of the mTOR-inhibitor everolimus in heart transplanted patients
Sign Up to like & getrecommendations! Published in 2017 at "Biomarkers"
DOI: 10.1080/1354750x.2016.1210676
Abstract: Abstract Context: Several assays of monitoring immune cell function have been developed to enhance therapeutic drug monitoring. Objective: An in vitro-validated whole-blood assay of phosphorylated ribosomal protein S6 (pS6RP) was evaluated for confounders to monitor… read more here.
Keywords: inhibitor everolimus; mtor inhibitor; phospho flow; therapeutic drug ... See more keywords
mTOR Inhibition and Clinical Transplantation: Liver.
Sign Up to like & getrecommendations! Published in 2018 at "Transplantation"
DOI: 10.1097/tp.0000000000001690
Abstract: The evidence base concerning use of mammalian target of rapamycin (mTOR) inhibitor therapy after liver transplantation is evolving rapidly, clarifying their benefits and disadvantages in different clinical scenarios. The H2304 trial showed that starting everolimus… read more here.
Keywords: mtor inhibitor; liver; transplantation; mtor ... See more keywords
mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28− Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection
Sign Up to like & getrecommendations! Published in 2019 at "Transplantation"
DOI: 10.1097/tp.0000000000002917
Abstract: Supplemental Digital Content is available in the text. Background. Renal allograft rejection is more frequent under belatacept-based, compared with tacrolimus-based, immunosuppression. We studied kidney transplant recipients experiencing rejection under belatacept-based early corticosteroid withdrawal following T-cell–depleting… read more here.
Keywords: therapy; mtor; histology; belatacept refractory ... See more keywords
Synergistic immunosuppression and unintended consequences
Sign Up to like & getrecommendations! Published in 2017 at "Pediatric Transplantation"
DOI: 10.1111/petr.13047
Abstract: In this issue, Ganschow et al1 describe their multicenter experience with 56 pediatric liver transplant recipients who were converted within the first 6 months from standard immunosuppression with calcineurin inhibitors (CNI) to a combination of… read more here.
Keywords: starting everolimus; mtor inhibitor; mtor; immunosuppression ... See more keywords
The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple Plasmodium kinases and life cycle stages
Sign Up to like & getrecommendations! Published in 2022 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.abo7219
Abstract: Compounds acting on multiple targets are critical to combating antimalarial drug resistance. Here, we report that the human “mammalian target of rapamycin” (mTOR) inhibitor sapanisertib has potent prophylactic liver stage activity, in vitro and in… read more here.
Keywords: sapanisertib; plasmodium kinases; plasmodium; activity ... See more keywords